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Modulation of the anti-nociceptive effects of
2-arachidonoyl glycerol by peripherally
administered FAAH and MGL inhibitors in a
neuropathic pain model
J Desroches1, J Guindon1, C Lambert1 and P Beaulieu1,2
1Department of Pharmacology, Universite´ de Montre´al—CHUM, Montre´al, Quebec, Canada and 2Department of Anesthesiology,
Faculty of Medicine, Universite´ de Montre´al—CHUM, Montre´al, Quebec, Canada
Background and purpose: There are limited options for the treatment of neuropathic pain. Endocannabinoids, such as
anandamide and 2-arachidonoyl glycerol (2-AG), are promising pain modulators and there is recent evidence of interactions
between anandamide and 2-AG biosynthesis and metabolism. It has been clearly demonstrated that 2-AG degradation is
mainly catalysed not only by monoacylglycerol lipase (MGL) but also by a fatty acid amide hydrolase (FAAH). Inhibitors
specifically targeting these two enzymes have also been described: URB602 and URB597, respectively. However, the anti-
nociceptive effects of the combination of peripherally injected 2-AG, URB602 and URB597 in a neuropathic pain model have
not yet been determined. This was performed in the presence or absence of cannabinoid CB1 (AM251) and CB2 (AM630)
receptor antagonists.
Experimental approach: Mechanical allodynia and thermal hyperalgesia were evaluated in 213 male Wistar rats allocated to
32 different groups. Drugs were injected subcutaneously in the dorsal surface of the hind paw (50 mL) 15 min before pain tests.
Key results: 2-AG, URB602 and URB597 significantly decreased mechanical allodynia and thermal hyperalgesia with ED50 of
1.6±1.5 and 127±83mg for 2-AG and URB602, respectively. These effects were mediated locally and were mostly inhibited by
the two cannabinoid antagonists.
Conclusions and implications: The combination of the three compounds did not produce any greater anti-allodynic or anti-
hyperalgesic effects, suggesting that FAAH inhibition could reduce or limit the anti-nociceptive effects of 2-AG. Peripheral
administration of endocannabinoids or MGL/FAAH inhibitors is a promising analgesic approach requiring further investigation.
British Journal of Pharmacology (2008) 155, 913–924; doi:10.1038/bjp.2008.322; published online 11 August 2008
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Introduction
Neuropathic pain is a complex disorder resulting from nerve
injury or insult to the peripheral or CNS. Unfortunately,
it is still considered to be relatively refractory to most of
the current analgesics, including opioids, emphasizing the
importance of identifying novel pharmacological agents for
its treatment. Recent treatment strategies have suggested
that cannabinoids may be more effective against chronic
than acute pain (Beaulieu and Ware, 2007).
There is accumulating evidence supporting the suggestion
that the endogenous cannabinoid system, mainly compris-
ing anandamide and 2-arachidonoyl glycerol (2-AG), may be
involved in pain modulation via the activation of two
distinct G-protein-coupled receptors, CB1 and CB2 (Pertwee,
2006; Di Marzo, 2008). The cannabinoid CB1 receptor is
primarily expressed at high levels in several brain areas and
throughout the CNS, including the spinal cord, in neurons
of the dorsal root ganglia and also in peripheral tissues
(Walczak et al., 2005, 2006; Agarwal et al., 2007; Lever and
Rice, 2007). By contrast, cannabinoid CB2 receptor expres-
sion seems to be found predominantly, but not exclusively,
in peripheral tissues with immune functions. It has also
recently been found in the brain, on dorsal root ganglia,
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in the lumbar spinal cord, on sensory neurons, on
microglia and in peripheral tissues (for review see Jhaveri
et al., 2007b).
Recent studies have demonstrated the anti-nociceptive
efficacy of cannabinoids in several animal models of
inflammatory and neuropathic pain (for review see Walker
and Hohmann, 2005). Moreover, it has been suggested that
cannabinoids can exert their anti-nociceptive action
through peripheral mechanisms involving CB1 and CB2
receptors (Sokal et al., 2003; Elmes et al., 2004; Jhaveri et al.,
2006; Gutierrez et al., 2007).
In neuropathic pain conditions, several studies have
shown that both CB1 (Agarwal et al., 2007) and CB2
(for review see Guindon and Hohmann, 2008) receptors
are involved in cannabinoid-induced anti-nociception at
peripheral sites. Furthermore, we have already shown that
local administration of anandamide into the hind paw
reversed mechanical allodynia and thermal hyperalgesia
by a mechanism involving only CB1 receptors (Guindon
and Beaulieu, 2006).
There is evidence that 2-AG acts as an endogenous
ligand, as a full agonist, for both CB1 and CB2 cannabinoid
receptors (Mechoulam et al., 1995; Sugiura and Waku, 2000),
with no direct binding to the TRPV1 receptor (Pertwee,
2006). However, it seems to act mostly as a potent and
full-efficacy agonist at the cannabinoid CB2 receptor
(Gonsiorek et al., 2000; Guindon et al., 2007). 2-AG is
mainly hydrolysed into arachidonic acid and glycerol by the
enzyme monoacylglycerol lipase (MGL) (Goparaju et al.,
1999; Dinh et al., 2004). However, evidence suggests that
2-AG might also be metabolized by another enzyme, fatty
acid amide hydrolase (FAAH), known to be responsible
for the degradation of anandamide (Bisogno et al.,
2005), and by two other previously uncharacterized serine
hydrolases ABHD6 and ABHD12 (Blankman et al., 2007).
A cautious interpretation is that both FAAH and MGL
participate in 2-AG inactivation to an extent depending
on the tissue or cell type (Di Marzo and Petrosino, 2007).
FAAH inhibitors have been described, such as URB597
(Kathuria et al., 2003), and FAAH knockout mice have been
developed (Cravatt et al., 2001). More recently, as MGL
knockout mice have not yet been described to investigate
the precise role of these enzymes in pain modulation,
MGL inhibitors, such as URB602 (Hohmann et al., 2005)
have been developed.
However, Vandevoorde et al. (2007) and Muccioli et al.
(2007) have recently questioned the selectivity of URB602
for MGL. In their study, in vitro URB602 was as effective at
inhibiting MGL as FAAH. Nevertheless, recent data using
both a purified recombinant MGL and intact brain neurons
unequivocally showed that URB602 successfully inhibits
MGL and blocks 2-AG hydrolysis in brain slices (King et al.,
2007).
Therefore, this study was designed to investigate the
peripherally mediated anti-nociceptive effects of 2-AG,
URB602 and URB597, after intraplantar injection, in a model
of neuropathic pain. The mechanism by which the three
compounds might produce their anti-nociceptive effect was
also investigated by using specific antagonists for the
cannabinoid CB1 and CB2 receptors.
Methods
Animals
The research protocol was approved by the Animal Ethics
Committee of the Universite´ de Montre´al, and all procedures
related to the use of animals conformed to the guidelines of
the Canadian Council for Animal Care. A total of 213 adult
male Wistar rats (Charles River, St-Constant, Quebec,
Canada) weighing 180–220 g, at the time of testing, were
housed, two per cage, in standard plastic cages with sawdust
bedding in a climate-controlled room, under a 12-h light/
dark cycle. They were allowed free access to food pellets and
water.
Drug administration
2-AG was purchased from Sigma (St Louis, MO, USA) in
acetonitrile solution and further diluted in normal saline
(0.9% NaCl in water). AM251 and AM630 are selective
antagonists for CB1 and CB2 receptors, respectively, and were
purchased from Tocris (Ellisville, MO, USA); they were
dissolved in normal saline containing 8 and 2.5% dimethyl
sulphoxide (DMSO), respectively. URB602 and URB597 were
purchased from Cayman Chemical (Ann Arbor, MI, USA) and
dissolved in normal saline containing between 1 and 10%
DMSO for the experimental doses. Preliminary experiments
with our model of neuropathic pain in rats (n¼4–6) have
shown that there was no difference in nociceptive responses
between the effects of 0.9% NaCl and 0.9% NaCl solution
with 8% DMSO (Guindon and Beaulieu, 2006). 2-AG,
URB602 and URB597 were stored at 20 1C, protected
from light and were prepared freshly on the day of the
experiment.
Neuropathic pain model
The partial sciatic nerve ligation (PNL) model was used in
this study to achieve unilateral hindlimb neuropathy (Seltzer
et al., 1990). Briefly, rats were anaesthetized using isoflurane
(induction, 3%; maintenance, 1–2%). The left sciatic nerve
was isolated under aseptic conditions and exposed at high
thigh level and a one-third to a one-half of the dorsal
thickness of the nerve was then tightly ligated using an 8-0
monofilament nylon suture. After surgery, the wound was
closed using 5-0 absorbable sutures for muscles and two
wound clips for the skin; the rats were allowed 9 days to
recover and their posture and behaviour were closely
monitored for 48 h. From day 10, rats were tested to assess
the development of mechanical allodynia and thermal
hyperalgesia. On the 11th day, drugs were administered
15 min prior to nociceptive testing.
Sensory testing
During sensory testing, animals were placed in elevated
Plexiglas boxes (21 1714 cm) with a 0.7 cm diameter
mesh grid floor for mechanical allodynia testing and a dry
glass floor for thermal hyperalgesia testing. Rats were
allowed to acclimatize for 15 min or until exploratory
behaviour ceased before behavioural testing. Effect of drugs
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with short half-lives, such as 2-AG, may be influenced by the
testing order. To minimize this effect, the sequence of testing
was alternated between mechanical allodynia and thermal
hyperalgesia. The time to complete one battery of tests was
approximately 40 min.
Mechanical allodynia
Mechanical sensitivity of the ipsilateral and contralateral
hindpaws was assessed using von Frey hairs (Senselab
aesthesiometer, Somedic, Sweden). Innocuous mechanical
punctuate stimuli were delivered to the plantar surface of the
hind paw with a series of individual von Frey filaments of
ascending forces (with a range comprised between 0.63 and
300 mN). For each filament, the stimulus was repeated five
times with an interval of 1–2 s between each trial. The
threshold was determined as the lower force that evoked a
withdrawal response to one of the five stimuli (Tal and
Bennett, 1994).
Thermal hyperalgesia
Thermal sensitivity of the ipsilateral and contralateral hind
paws was assessed using an infrared noxious heat stimulus of
increasing temperature range, from non-noxious to noxious
range (Plantar test, Ugo Basile, Italy). Thermal punctuate
stimuli were delivered to the plantar surface of the hind paw
with a focused beam of radiant heat, and the withdrawal
latency time was recorded. Results of each test are expressed
as the mean of three withdrawal latencies in seconds (s).
Three minutes was allowed between each test (Hargreaves
et al., 1988).
Experimental protocols
The experiments were conducted in a randomized and
blinded manner by the same experimenter. Mechanical
allodynia and thermal hyperalgesia were evaluated the day
before PNL and on the 10th day after PNL for the ipsilateral
and contralateral paws to confirm that rats were neuro-
pathic.
Dose–response curves for 2-AG (0.001–0.01–0.1–1–3–10–
30–100 mg; n¼4–6 per group) and URB602 (0.1–1–10–100–
1000 mg; n¼4–6 per group) for mechanical allodynia and
thermal hyperalgesia were determined.
On the 11th day, rats were allocated to 32 different groups:
(1) a control group for each set (five) of experiments
(NaCl 0.9%); (2) 2-AG (10 mg); (3) AM251; (4) AM251þ
2-AG; (5) AM630; (6) AM630þ2-AG; (7) URB602 (300 mg);
(8) AM251þURB602; (9) AM630þURB602; (10) URB597
(25 mg); (11) AM251þURB597; (12) AM630þURB597;
(13) 2-AG (ED50); (14) URB602 (ED50); (15) 2-AGþURB602;
(16) 2-AGþURB597; (17) 2-AGþURB602þURB597. 2-AG,
URB602, URB597 (25 mg; Jhaveri et al., 2006), AM251 (80 mg;
Malan et al., 2001) and AM630 (25 mg; Malan et al., 2001)
were all dissolved in the same total volume of 50 mL and
administered subcutaneously (s.c.) in the dorsal surface of
the operated left hind paw, 15 min before pain tests (n¼6 per
group).
To exclude any possible systemic effect of the drugs, NaCl
0.9%, 2-AG, URB602 and URB597 were also given subcuta-
neously on the dorsal surface of the contralateral side (right
hind paw) (n¼6 per group).
Statistical analysis
Mechanical threshold and withdrawal latency for each
treatment group are expressed as mean±s.e.mean. Assess-
ment of the neuropathy, comparisons between rats receiving
NaCl 0.9%, AM251 or AM630 and analgesic effects of 2-AG,
URB602, URB597 and their combination with regard to the
absence or presence of antagonists (AM251 or AM630) were
all assessed separately for significance using an ANOVA
adapted for factorial experimental design (Winer, 1971;
Draper and Smith, 1998). Each of the analyses mentioned
above was assessed for mechanical allodynia and thermal
hyperalgesia of the ipsilateral side. The contralateral side was
analysed separately, still using an ANOVA adapted for
factorial experimental design. The dose–response curves for
2-AG and URB602 were determined using ALLFIT software
(De Le´an et al., 1978). The critical level of significance was set
at 5% (Po0.05).
Results
Animals showed signs of neuropathy 10 days after PNL, as a
statistically significant difference was present, in comparison
with pre-surgery values, for mechanical allodynia (F(1, 94)¼
142.65, Po0.001) (Figure 1a) and thermal hyperalgesia
(F(1, 94)¼144.45, Po0.001) (Figure 1b).
Mechanical allodynia
2-AG and URB602 produced a dose-dependent anti-allodynic
effect with ED50 of 1.6±1.5 and 127±83 mg, respectively
(Figures 2a and 3a). However, a light local intolerance
was observed following intraplantar injection of URB602
(1000 mg in 50 mL). This was probably an irritation, so we
avoided using this dose. URB597, URB602, 2-AG and
their combination produced a significant anti-allodynic
effect, when compared with the control group (F(1, 35)¼
15.68, Po0.001) (Figure 4a). The combination of 2-AG
with URB602 or with URB602þURB597 was significantly
different when compared with URB597, URB602, 2-AG or
2-AGþURB597 (F(1, 35)¼12.93, Po0.005) (Figure 4a), reveal-
ing a superior anti-nociceptive effect of those combinations.
von Frey values obtained in animals after PNL were not
affected by treatment with NaCl 0.9%, AM251 or AM630
(F(1, 16)¼0.01) (Table 1). Furthermore, values in the control
group were not different from values obtained with both
cannabinoid antagonists (F(1, 16)¼0.01). Finally, results in
the AM251 group were not different from those found in the
AM630 group (F(1, 16)¼0.02) (Table 1).
In the absence of cannabinoid antagonists, 2-AG, URB602
and URB597 produced significant anti-allodynic effects,
when compared with control group (F(1, 30)¼80.41, 52.57
and 4.48), with values returning to pre-surgical levels
(Figures 5a, 6a and 7a).
In the presence of AM251 and AM630, the anti-allodynic
effects of 2-AG and URB602 were inhibited, as there was no
2-AG peripheral anti-nociceptive effects
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statistical difference for the comparison between CB1 and
CB2 antagonists alone or combined with 2-AG (F(1, 30)¼
0.61 and 0.14, respectively) (Figure 5a) and with URB602
(F(1, 30)¼0.01 and 0.01, respectively) (Figure 6a). The
combination of URB597þAM251 (CB1 antagonist) did not
produce any anti-allodynic effects, when compared with
AM251 alone (F(1, 30)¼0.95). By contrast, the combination
of URB597þAM630 (CB2 antagonist) did produce significant
anti-allodynic effects, when compared with AM630 alone
(F(1, 30)¼5.32) (Figure 7a). Finally, there was no difference
between all the groups tested on the contralateral side
(Figures 4a, 5a, 6a and 7a, insets).
When the drugs were given on the contralateral side to rats
after PNL (F(1, 30)¼265.32, Po0.001), there was no
statistical difference between days 10 and 11 (that is, before
and after local drug administration) (F(1, 30)¼0.01) on
the ipsilateral (tested) side (Figure 8a). On the contralateral
side, there was no difference between the day before the
surgery (pre-lesion) compared with the days after surgery
(days 10 and 11) (F(1, 30)¼0.49), and no difference was
observed between days 10 and 11 (F(1, 30)¼0.77) (Figure 8a,
inset).
Thermal hyperalgesia
2-AG and URB602 also produced a dose-dependent anti-
hyperalgesic effect with ED50 of 0.20±0.19 and 86±52 mg,
respectively (Figures 2b and 3b). 2-AG, URB602, URB597
and their combination produced a significant anti-
hyperalgesic effect, when compared with the control group
(F(1, 35)¼38.74, Po0.001) (Figure 4b). The combination
of 2-AG with URB602 or with URB602þURB597 was not
significantly different when compared with 2-AG, URB602,
URB597 or 2-AGþURB597 (F(1, 35)¼2.67), showing
that there was no greater anti-nociceptive effect of the
combinations.
Responses to the noxious heat stimulus obtained after PNL
were not different (F(1, 16)¼0.02) from those measured
when rats received NaCl 0.9%, AM251 or AM630. Further-
more, values in the control group were not different
from values obtained with both cannabinoid antagonists
(F(1, 16)¼0.35). Finally, results in the AM251 group
were not different from those found in the AM630 group
(F(1, 16)¼0.05) (Table 1).
In the absence of cannabinoid antagonists, 2-AG, URB602
and URB597 produced significant anti-hyperalgesic effects,
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Figure 1 Mechanical allodynia using von Frey hair (a) and thermal hyperalgesia using infrared noxious heat stimulus (b) before surgery
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when compared with control group (F(1, 30)¼26.67, 32.58
and 31.59, respectively, Po0.001) with values returning to
pre-surgical levels (Figures 5b, 6b and 7b).
In the presence of AM251 and AM630, the anti-hyper-
algesic effects of 2-AG and URB602 were inhibited, as there
was no statistical difference for the comparison between
CB1 and CB2 antagonists alone or combined with 2-AG
(F(1, 30)¼1.45) (Figure 5b) and URB602 (F(1, 30)¼1.32)
(Figure 6b). However, the anti-hyperalgesic effects of URB597
were reversed by the CB1 antagonist AM251 (F(1, 30)¼0.37),
but were not inhibited by the CB2 antagonist AM630
(F(1, 30)¼15.26) (Figure 7b). Finally, there was no difference
between all the groups tested on the contralateral side
(Figures 4b, 5b, 6b and 7b, insets).
When the drugs were given on the contralateral side to
rats after PNL (F(1, 30)¼254.56, Po0.001), there was no
statistical difference between days 10 and 11 (F(1, 30)¼ 0.42)
on the ipsilateral side (Figure 8b). On the contralateral side,
there was no difference between the day before the surgery
(pre-lesion) compared with the days after surgery (days 10
and 11) (F(1, 30)¼0.01), and no difference was observed
between days 10 day 11 (F(1, 30)¼0.30) (Figure 8b, inset).
Discussion
In this study, we have demonstrated that local administra-
tion of 2-AG, an endocannabinoid, URB602, a MGL inhibitor
and URB597, a selective FAAH inhibitor, induced anti-
allodynic and anti-hyperalgesic effects in a rat model of
neuropathic pain. These anti-nociceptive effects were locally,
rather than systemically, mediated, as 2-AG, URB602 and
URB597 injected in the contralateral paw did not produce
anti-nociceptive effects at doses higher than those used in
the ipsilateral paw. Furthermore, these effects were likely to
be mediated by cannabinoid CB1 and CB2 receptors, as anti-
nociceptive effects of intraplantar 2-AG and URB602 were
prevented by the selective CB1 and CB2 receptor antagonists,
AM251 and AM630, respectively. However, the anti-nocicep-
tive effects of intraplantar URB597 were not prevented by
AM630, confirming the fact that URB597 produces its effects
via direct or indirect activation of CB1 receptors. Thus, these
findings suggest that the activation of peripheral CB1
and CB2 receptors by endocannabinoids or with MGL and
FAAH inhibitors are sufficient to produce anti-allodynic and
anti-hyperalgesic effects.
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Figure 2 Dose–response curve for 2-arachidonoyl glycerol (2-AG)
for mechanical allodynia using von Frey hair (a) and for thermal
hyperalgesia using infrared noxious heat stimulus (b). Data are
expressed as mean±s.e.mean (n¼4–6 per group).
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Figure 3 Dose–response curve for URB602 for mechanical allodynia
using von Frey hair (a) and for thermal hyperalgesia using infrared
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We have shown that 2-AG produced dose-dependent anti-
nociceptive effects and significantly decreased mechanical
allodynia and thermal hyperalgesia with ED50 in the
microgram range, whereas a recent study from our group
showed that anandamide was also anti-nociceptive but with
doses in the nanogram range (Guindon and Beaulieu, 2006).
In fact, anandamide is a partial or full agonist of CB1
receptors: it mainly mediates its anti-nociceptive effects
through the activation of CB1 receptors and its pro-
nociceptive effects through TRPV1 receptors (Maccarrone
et al., 2008). Although it also binds CB2 receptors, it has very
low efficacy and may act as an antagonist (Gonsiorek et al.,
2000). In contrast, 2-AG acts as an agonist for both CB1 and
CB2 receptors to modulate pain transmission in a model of
neuropathic pain (Saario and Laitinen 2007).
MGL inhibitors such as URB602 (Hohmann et al., 2005)
and selective FAAH inhibitors such as URB597 (Kathuria
et al., 2003; Jayamanne et al., 2006) have been described.
URB602 potentitates endocannabinoid-dependent stress-
induced analgesia following local administration into either
the periaqueductal grey or lumbar dorsal horn (Hohmann
et al., 2005; Suplita et al., 2006). Accordingly, ultrastructural
studies suggest that MGL is localized predominantly, if not
exclusively on axon terminals (Gulyas et al., 2004). Thus,
peripherally injected MGL inhibitors, as demonstrated in
this study, could offer significant therapeutic potential for
the treatment of neuropathic pain.
Although URB602 is an inhibitor of MGL, it has low
potency (Hohmann et al., 2005). In addition, Begg et al.
(2005) have recently shown evidence for cannabinoid
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receptors beyond CB1 and CB2. Thus, 2-AG anti-nociceptive
action and degradation appear to be complex, to involve
multiple enzymes and could vary between cell types. In fact,
Muccioli et al. (2007) have reported the existence of a
novel, pharmacologically distinct MGL that opens promis-
ing therapeutic avenues. However, our current knowledge
of the roles of 2-AG in pain modulation is still limited, due
to the lack of mutant MGL/ mice that are incapable
of synthesizing or inactivating 2-AG. Nevertheless, we
then wanted to evaluate whether 2-AG degradation could
be affected both by MGL and by FAAH inhibitors. In fact,
the addition of URB597, either with 2-AG or with 2-AG
and URB602, failed to produce a significant additive
anti-nociceptive effect. These results are in agreement with
a recent publication by Maccarrone et al (2008), suggesting
a ‘reconceptualization’ of the endocannabinoid system.
Indeed, they proposed that anandamide and 2-AG
may cooperate to modulate synaptic transmission. In fact,
they have demonstrated that the elevation of anandamide
concentrations by either pharmacological or genetic inhibi-
tion of FAAH can interfere with 2-AG levels, metabolism
and physiological effects through the activation of TRPV1
receptors in the striatum (Maccarrone et al., 2008). This
interaction could also be present in the periphery, as
Table 1 Mechanical allodynia using von Frey and thermal hyperalgesia
using infrared noxious heat stimulus before, 10 and 11 days after surgery
Mechanical
threshold (mN)
Withdrawl
latency (s)
Mean ±s.e.mean Mean ±s.e.mean
Pre-lesion baseline 301 90.8 11.4 1.7
10 days after PNL 50.9 11.3 6.9 0.6
11 days after PNL-NaCl 49.2 1.1 6.6 0.6
11 days after PNL-AM251 53.2 7.5 7.4 0.6
11 days after PNL-AM630 45.5 0.3 7.1 0.8
Abbreviation: PNL, partial sciatic nerve ligation.
On the 11th day, rats received NaCl 0.9%, AM251 (cannabinoid CB1
antagonist; 80 mg) and AM630 (cannabinoid CB2 antagonist; 25mg) on the
ipsilateral side. Data are expressed as mean±s.e. mean (n¼4–6 per group).
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nociceptive primary sensory neurons co-express CB1 and
TRPV1 receptors to a very high degree (Ahluwalia et al.,
2000). However, it may not be adequate to apply this new
concept, based on findings in the CNS, to events in the
periphery.
Several recent studies have reported that both peripheral
CB1 (Agarwal et al., 2007) and CB2 (for review see Guindon
and Hohmann, 2008) receptors are involved in anti-
allodynic and anti-hyperalgesic effects of locally injected
cannabinoids after nerve injury. In peripheral tissues, the
expression of CB1 and CB2 receptors in rats and mice has
been well described not only at basal level, but was also
upregulated in the paw, DRG and ipsilateral spinal cord of
rats in a new model of neuropathic pain, targeting the
saphenous nerve (Walczak et al., 2005, 2006). Similarly,
Mitrirattanakul et al. (2006) have reported that CB1 receptors
are upregulated in DRG following the development of
neuropathic pain, thereby providing hope for the use
of compounds targeting the peripheral endocannabinoid
system. Furthermore, studies of knockout mice have con-
firmed that CB1 and CB2 receptors are involved in cannabi-
noid-induced analgesia (Ledent et al., 1999; Zimmer et al.,
1999; Ibrahim et al., 2006), but have not revealed their
precise site of action. To resolve this question, Agarwal et al.
(2007) generated transgenic mice lacking CB1 receptors in
nociceptive neurons localized in the peripheral nervous
system of mice, preserving expression in spinal neurons, the
brain and all other organs. They showed that CB1 receptors
on nociceptors, and not those within the CNS, constitute
an important target for mediating cannabinoid analgesia
(Agarwal et al., 2007). However, one cannot rule out compen-
satory effects in transgenic mouse models. Furthermore,
previous studies have reported that endocannabinoids, such
as anandamide and 2-AG, are present in peripheral tissues
(Beaulieu et al., 2000; Jhaveri et al., 2006; Mitrirattanakul
et al., 2006). Elevation of endocannabinoids levels has
been demonstrated in paw tissues following tissue injury
(Calignano et al., 1998; Oka et al., 2005; Mitrirattanakul
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et al., 2006), in the spinal cord during L5–L6 spinal nerve
ligation (Jhaveri et al., 2006) and chronic constriction injury
of the sciatic nerve (Petrosino et al., 2007). Therefore,
endocannabinoid levels in neuropathic pain conditions are
consistently reported to be increased at many sites involved
in the nociceptive processing (Jhaveri et al., 2007a). Indeed,
Jhaveri et al. (2006) have recently demonstrated that intra-
plantar injection of URB597 suppressed the mechanically
evoked responses of wide dynamic-range spinal neurons in
sham-operated rats and increased anandamide and 2-AG
levels. However, a higher dose of intraplantar URB597 was
required to attenuate evoked responses of spinal neurons in
nerve-ligated rats, but surprisingly failed to alter hind paw
levels of endocannabinoids. The authors suggested that
these levels may have been affected by other metabolic
pathways, such as cyclooxygenase-2 (COX-2), or alterations
of peripheral FAAH activity (Jhaveri et al., 2006). Measure-
ment of endocannabinoid levels in peripheral paw tissue was
not performed in the present study. The absence of such
measures is a weakness and to that extent, the results
presented herein do not contribute to the debate regarding
the specificity of URB602 for MGL inhibition. It is, however,
interesting to note that in a recent publication, concerns
were raised about the correlation between the amounts
of endocannabinoids measured in tissues and extracellular,
and hence CB receptor-active, levels of endocannabinoids
(Di Marzo, 2008). Endocannabinoids might be present in
high concentrations to inhibit pain transmission by acting
on CB1 and CB2 receptors, which have also been found to
be upregulated in several regions of the pain pathway.
Therefore, the anti-nociceptive effects of 2-AG may be
mediated by a direct action on cannabinoid CB1 and CB2
receptors located in the injected paw.
Other mechanisms to explain the peripheral anti-
hyperalgesic action of cannabinoids may be linked to the
anti-inflammatory effects of these compounds in peripheral
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tissues; CB1 and CB2 receptor agonists could act locally at the
level of the peripheral axon of the primary afferent neuron
and indirectly inhibit transmission in nociceptive afferents
by reducing the inflammatory component of tissue injury. In
fact, recent studies have reported that cannabinoids can
reduce the production and release of pro-inflammatory
signalling molecules, such as tumour necrosis factor-a, nitric
oxide and interleukin-1 (IL-1), and enhance the release of
anti-inflammatory cytokines like the IL-1 receptor antago-
nist, IL-4 and IL-10 (Walter and Stella, 2004). Moreover,
another hypothesis is that the activation of CB2 cannabinoid
receptors may stimulate the local release of the endogenous
opioid endorphin from cells such as keratinocytes (Ibrahim
et al., 2005). These authors have postulated the release of
b-endorphin by AM1241, a CB2 selective agonist, acting
on CB2 receptors in skin keratinocytes, as a mechanism to
explain the peripheral analgesic actions of this compound.
Therefore, endocannabinoids such as anandamide and 2-AG
may interact directly or indirectly with cannabinoid recep-
tors on the peripheral endings of cutaneous nociceptives
sensory neurons to modulate the transmission of nociceptive
signals to the spinal cord.
The anti-nociceptive effects of peripherally administered
cannabinoids need to be counterbalanced by the fact
that many reports have already demonstrated anti-
nociceptive properties of central (cerebral and spinal)
administrations of cannabinoid receptor agonists (for review
see Hohmann et al., 2005; Lever and Rice, 2007), whereas
others have questioned the involvement of CB1 receptors
in the analgesia evoked by peripheral administration of
cannabinoids.
In conclusion, these findings are the first to demonstrate
that peripherally injected 2-AG, URB602, URB597 and
their combination decreased pain behaviour in a model
of neuropathic pain. This study provides evidence that
the activation of cannabinoid CB1 and CB2 mechanisms in
the periphery is sufficient to decrease nociception in
an animal model of neuropathic pain. Finally, as cannabi-
noid-based drugs seem to be effective for the treatment
of neuropathic pain, this approach is of potential thera-
peutic importance because it may present a way of delivering
the analgesic benefit of cannabinoid compounds while
avoiding troublesome psychotropic and other systemic
effects.
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